Selective progesterone receptor modulators (SPRMs) offer novel and unique medical treatment options in gynecology [1] and the potential of SPRM for the treatment of uterine fibroids has been well established [2]. The gene discussed is PGR; the disease is uterine corpus leiomyoma.